Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T15:42:41.329Z.
Calculation as of: 2026-10-06T15:42:41.329Z.
Quote observation: 2026-10-06T15:40:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a8aae8e93f82a899e51ff603ce0499f2ee8a4244ac8b174beef8711f00adb15
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Spectral AI, Inc.
Market Cap
$54.74M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Spectral AI, Inc. (MDAI) | $54.74M | N/A |
| Aldeyra The (ALDX)vs › | $54.53M | N/A |
| ImageneBio Inc (IMA)vs › | $53.80M | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.78M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.61M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.98M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.44M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
